The current cardiac safety situation with antihistamines

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 1, 1999, Pages 15-24

  Yap, Yee Guan ^a,b   Camm, A J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antihistamines; QT interval; Torsades de pointes; Ventricular repolarization

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; POTASSIUM CHANNEL; TERFENADINE;

ALLERGY; ANTICHOLINERGIC EFFECT; CONFERENCE PAPER; HEART ARRHYTHMIA; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT INTERVAL; SEDATION; TORSADE DES POINTES;

BENZIMIDAZOLES; HEART DISEASES; HISTAMINE H1 ANTAGONISTS; HUMANS;

EID: 0032967949     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36:233-52.
2. Davies AJ, Harinda V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. Br Med J, 1989; 298:325 (Abstract).
3. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occuring in association with terfenadine use. J Am Med Assoc 1990; 264:2788-90.
4. Zimmerman M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13:1002-3.
5. Honig PK, Wortham DC, Zamani K, Connor DP, Mulin JC, Cantilena LR. Terfenadine-ketoconazole interaction. JAMA 1993; 269:1513-8.
6. Zechnich AD, Hedges JR, Eiselt-Proteau D, Haxby D. Possible interactions with terfenadine or astemizole. West J Med 1994; 160:321-5.
7. Woosley RL, Chen Y, Freiman JP, Gilles RA. Mechanism of the cardiotoxic actions terfenadine. J Am Med Assoc 1993; 269:1532-6.
8. Rankin AC. Non-sedating antihistamines and cardiac arrhythmia. Lancet 1997; 349:1115.
9. Zhang M-Q. Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem 1997; 4:171-84.
10. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier current: differential sensitivity to block by class III antiarrhythmic agents. Gen Physiol 1990; 96:195-215.
11. Sakmann B, Trube G. Conductance properties of single inwardly rectifying potassium channels in ventricular cells from guinea pig heart. J Physiol 1984; 347:641-57.
12. Rees S, Curtis MJ. Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmia? Pharmacol Ther 1996; 69:199-217.
13. Sicouri S, Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep sub-epicardium of the canine ventricle. The M cell. Circ Res 1991; 68:1729-41.
14. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81:299-307.
15. Yang WP, Levesquc PC, Little AL, Conder ML, Shalaby EY, Blanar MA. KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias. Proc Nat Acad Sci 1997; 94:4017-21.
16. Wang Q, Shen J, Splawski I, et al. SNC5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80:805-11.
17. Roy ML, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94:817-23.
18. Snyders DJ, Shaudary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 1996; 49:949-55.
19. Ko CM, Ducic I, Fan J, Shuba YM, Morad M. Suppression of mammalian K + channel family by ebastine. Pharmacol Exp Ther 1997; 281:233-44.
20. Ducic I, Ko CM, Shuba Y, Morad M. Comparative effects of loratadine and terfenadine on cardiac K + channels. J Cardiovasc Pharmacol 1997; 30:42-54.
21. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in xcnopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS 1996; 385:77-80.
22. Biton B, Maitre S, Godet D, et al. Effect of the novel non-sedative histamine H1 receptor antagonist mizolastine on cardiac potassium and sodium currents. Allergy 1998; 53:419 (Abstract).
23. Morganroth J. Relationship of QTc prolongation on the electrocardiogram to torsades de pointes: defenitions and mechanisms. Am J Cardiol 1993; 72:10B-13B.
24. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72:23B-25B.
25. Roden DM, Torsades de Pointes. Clin Cardiol 1993; 16:683-6.
26. Spencer CM, Fauld D, Peters DH, Cetirizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 1993; 46:1055-80.
27. Haria M, Fitton A, Peters DH. Loratidine-A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994; 48:617-37.
28. Heykants J, Van Peer A, Woestenborghs R, Jageneau A, Van den Bussche G. Dose proportionality, bioavailability and steady-state kinetics of astemizole in man. Drug Dev Res 1986; 8:71-8.
29. Robbins DK, Castles MA, Pack DJ, Bhargava VO, Wein SJ. Comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16, 445) and its enantiomers. Pharm Res 1996; 13:S430.
30. Lalonde RL, Lessard D, Gaudreault J. Population pharmacokinetics of terfenadine. Pharm Res 1996; 13: 832-8.
31. 1) antagonists. Allergy 1995; 50:12-6.
32. Leeson GA, Chan KY, Knapp WC, Biedenbach SA, Wright GL, Okerholm RA. Metabolic disposition of terfenadine in laboratory animals. Arzneimittelforschung 1982; 32:1173-8.
33. Michiels M, Van Peer A, Woestenborghs R, Heykants J. Pharmacokinetics and tissue distribution of astemizole in the dog. Drug Dev Res 1986; 8:53-62.
34. 1-receptor antagonists astemizole and terfenadine compared with chlopheniamine and pyrilamine. Circ Res 1995; 76:110-9.
35. Lindquist M, Edwards IR. Risks of non-sedating anti-histamines. Lancet 1997; 349:1322 (letter).
36. Cohen AT. Dangers of non-sedating antihistamines. Lancet 1997; 350:69-70 (letter).
37. Himmel MH, Honig PK, Worobec AS. Dangers of non-sedating antihistamines. Lancet 1997; 350:69-70 (letter).
38. Wood SG, John BA, Chasseaud LF, Yeh J, Chung M. The metabolism and pharmacokinetics of 14C cetirizine in human. Ann Allergy 1987; 59:31-4.
39. Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, Cayen MN. Identification of human liver cytochrome P-450 enzymes that metabolise the non-sedating antihistamine loratidine: formation of the decarboethoxyloratidine by CYP 3A4 and CYP 2D6. Biochem Pharmacol 1996; 51:165-72.
40. Lavrijsen K, Van Houldt J, Meuldermans W, Janssens M, Heykants J. The interaction of ketoconazole, itraconazole and erythromycin with the in-vitro metabolism of anti-histamines in human liver microsomes. Eur J Clin Immunol 1993; 48:34.
41. Ling KHJ, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK. Metabolism of terfenadine associated with CYP3A (4) activity in human hepatic microsomes. Drug Metab Dispos 1995; 23:631-6.
42. Yun CC, Okerholm A, Guengerich PF. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450, 3A (4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993; 21:403-409.
43. Lippert C, King KHJ, Brown P, Burmaster SD, Eller M, Cheng LK et al. Mass-balance and pharmacokinetics of MDL 16, 445 A in healthy male volunteers. Pharm Res 1995; 12:PPDM 8253.
44. Stevens JC, Berger PL, Bordeaux KG. Metabolism of ebastine by human liver microsomes and c-DNA-expressed cytochrome P450 forms. Proceedings Fifth European ISSX Meeting Tours, France; 1993: Abstract 66.
45. Garson A. How to measure QT interval-what is normal? Am J Cardiol 1993; 72:14B-16B.
46. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993; 72: 17B-22B.
47. Fish FA, Roden DM. A prolonged QTc interval. Is it an important effect of anti-arrhythmic drugs? Med Toxic Adv Drug Exp 1989; 4:400-11.
48. Thomas SHL. Drugs, QT interval abnormalities and ventricular arrhythmias. Adv Drug Reacti Acute Toxocol Rev 1994; 13:77-102.
49. 1 antihistamine. Clin Exp Allergy 1999; 29(Suppl. 2): in press.
50. Paserchia LA, Hewett J, Woosley RL. Effect of ketoconazole on QTc. Clin Pharmacol Ther 1994; 55:146 (Abstract).
51. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine (Seldene) and QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996; 131: 472-80.
52. Sale ME, Barbey JT, Woosley RL et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994; 54:295-301.
53. Affrime MB, Lorber R, Danzig M, Cuss F, Brannan MD. Three month evaluation of electrocardiographic effects of loratidine in humans. Allergy 1993; 48:1215 (Abstract).
54. Hii JTY, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsades de pointes. Circulation 1992; 86:1376-82.
55. Houltz B, Darpo B, Edvardsson N, et al. Electrocardiogra-phic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. PACE 1998; 21:1044-57.
56. Thomas SHL. Drugs and the QT interval. Adv Drug Reac Bull 1997; 182:691-4.